- Trial phase
- Approved (marketed); supplemental/expansion trials Phase 3
- Time to market
- Already on the market, accelerated US approval 2016 (17p-deleted CLL), broader CLL/SLL approval 2019, AML approvals since 2018-2020, and newest first-line CLL combo approval February 2026.
- Why 4/10
- No hard, dated binary for Venclexta in the next ~12 months: the most recent catalyst, FDA approval of the Venclexta + acalabrutinib first-line CLL combo, already passed (Feb 19-20, 2026), the VERONA MDS expansion trial failed, and the drug is one (solid but minority) franchise inside mega-cap AbbVie, so impactScore sits mid-range at 4.
The defining approvals are already in: Venclexta is a marketed CLL/AML franchise with a fresh US label expansion (first-line CLL combo, Feb 2026), so there is no pending PDUFA-style binary to trade, the next meaningful moves will come from quarterly hematology revenue commentary and competitive data from next-generation BCL-2 inhibitors (e.g., BeiGene's sonrotoclax). ABBV's stock is driven far more by its immunology portfolio (Skyrizi/Rinvoq) than by Venclexta, so position sizing should treat this drug as steady cash flow, not a swing factor.
Price Chart
Executive Summary
Venclexta (venetoclax, also sold as Venclyxto outside the US) is an approved oral BCL-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma and acute myeloid leukemia, developed by AbbVie with Roche/Genentech, confirmed via FDA pages, AbbVie press releases, and SecBot's FDA-catalyst log. In February 2026 the FDA approved the all-oral, fixed-duration Venclexta + acalabrutinib combo for previously untreated CLL, and nine-year CLL14 data were showcased at EHA 2026, but the Phase 3 VERONA trial failed to improve survival in myelodysplastic syndrome, a setback for label expansion. ABBV (NYSE, confirmed live issuer) trades near $251 with a buy-rated analyst consensus (mean target ~$270), but Venclexta is one of several growth franchises inside the mega-cap, so it has no near-term binary catalyst.
How It Works
A once-daily pill that blocks a protein called BCL-2, which acts as a "survival switch" inside cancer cells. Blocking it makes leukemia/lymphoma cells self-destruct while leaving most healthy cells alone; it is used alone or combined with other cancer drugs (e.g., acalabrutinib, obinutuzumab, azacitidine).
Trial Status
FDA approved the Venclexta + acalabrutinib sNDA for previously untreated CLL in Feb 2026 (Phase 3 AMPLIFY data); final 9-year results from the Phase 3 CLL14 first-line CLL trial were presented at EHA June 2026; Phase 3 VERONA trial (venetoclax + azacitidine in higher-risk MDS) showed no overall survival benefit, presented 2025; AbbVie presented Phase 3 CANOVA results (relapsed/refractory multiple myeloma, t(11;14)) in 2023; a post-transplant AML maintenance Phase 3 study was terminated.
The Two-Sided Case
Upcoming Catalysts
- Quarterly earnings commentary on hematology-oncology revenue (Q2 2026 8-K filed July 31, 2026; FY2026 revenue consensus ~$67.6B).
- Potential ex-US (e.g., EMA) regulatory actions on the Venclexta + acalabrutinib first-line CLL combo, no confirmed date from sources reviewed.
- Competitive readouts from next-gen BCL-2 inhibitors (sonrotoclax) that could pressure the CLL market.
- Any follow-on filings from VERONA (MDS, unlikely after the survival miss) or CANOVA (multiple myeloma), both currently lack a dated submission.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report